Vigilare Wealth Management Fate Therapeutics Inc Transaction History

Vigilare Wealth Management

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 19, 2021	SELL	$59.27 - $95.73 $165,956 - $268,044	-2,800 Closed	0 $0
Q2 2021 Jul 16, 2021	BUY	$67.25 - $92.52 $188,300 - $259,056	2,800 New	2,800 $243,000
Q1 2021 Apr 29, 2021	SELL	$72.16 - $117.4 $172,823 - $281,173	-2,395 Closed	0 $0
Q4 2020 Jan 14, 2021	SELL	$38.09 - $100.95 $135,409 - $358,877	-3,555 Reduced 59.75%	2,395 $218,000
Q3 2020 Oct 15, 2020	SELL	$30.41 - $40.5 $22,199 - $29,565	-730 Reduced 10.93%	5,950 $238,000
Q2 2020 Jul 20, 2020	BUY	$20.21 - $35.23 $135,002 - $235,336	6,680 New	6,680 $229,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $222M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Vigilare Wealth Management, based on Form 13F filings with the SEC.

Stay updated on Vigilare Wealth Management with notifications on news.